Chronic Fatigue Syndrome Trial, Recruiting NCT07529197 Sponsor: Charite University, Berlin, Germany Condition: Chronic Fatigue Syndrome
Back to Chronic Fatigue Syndrome

Chronic Fatigue Syndrome Trial, Recruiting

NCT07529197
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old and able to agree to take part in the study
  • You have been diagnosed with ME/CFS using specific diagnostic guidelines (called the Canadian Consensus Criteria), which includes experiencing worsening of symptoms after activity (known as "post-exertional malaise") that lasts at least 14 hours
  • Your ME/CFS significantly limits your daily functioning, based on a specific disability scale (Bell Disability Score between 30 and 60)
  • A blood test has shown the presence of certain immune system proteins (called autoantibodies) that affect the nervous or hormonal system
  • You are already scheduled to receive a specific blood-filtering treatment called immunoadsorption (IA) using a TheraSorb® device, carried out over 5 days
  • You are willing and able to sign a written consent form
  • You have health insurance coverage

Who may not be able to join:

  • You are not willing to allow your anonymised health data to be stored as part of the study
  • You are pregnant
  • You have another health condition that could explain your symptoms instead of ME/CFS, such as heart failure, lung disease, severe depression, or cancer
  • You currently have an active infection such as COVID-19, HIV, or hepatitis
  • Your ME/CFS is so severe that you are largely or completely confined to bed (Bell Disability Score below 30)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Carmen Scheibenbogen, Prof. Dr., Institute of Medical Immunology, Charité - Universitätsmedizin Berlin,

Phone: +49 450 624354

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
11 March 2026
Est. completion
30 June 2027

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Improvement in Physical Function (PF) as measured by the Short Form 36 Health Survey Questionnaire (SF-36)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov